About

Our Story

Our culture of innovation and collaboration unlocks the next generation of scientific innovations​

About Us

What we do

Laverock is using its unique platform technologies to develop novel therapeutic approaches, addressing areas of significant unmet clinical need through disease responsive advanced therapies​

2021

Laverock secures pre-seed funding and spins-out from Tropic Biosciences, with exclusive license to gene silencing technology for human cell applications

2021

Operations established at Stevenage Bioscience Catalyst​

2023

Laverock secures £0.5m SMART grant from Innovate UK to validate gene silencing platform for engineering iPSC-derived cell therapies

2023

Laverock raises £13.5m as seed financing round​, lead by Calculus Capital, with participation from Eli Lilly and Company, Mercia Ventures, Eos Advisory, Maven Capital Partners, UK Innovation & Science Seed Fund, and Tekfen Ventures

2023

Laverock secures £1m grant from Innovate UK to support generation of engineered immune effector cells​

2024

Laverock provides key updates on platform exemplification and therapeutics pipeline definition

2025

Company relocates to Tribeca development in London's Knowledge Quarter in Kings Cross​

2025

Company reports close of further seed financing, taking total raised to in excess of £20m, along with achieving key milestones in T cell and Macrophage oncology programs

About Us

What exactly is a Laverock?​

Laverock is a Scots word that means Lark – we chose the name to capture this dynamic, agile and flightful image and apply this in our vision of how a Biotech company should be…​

Learn more